Serum IGF-1 Scores and Clinical Outcomes in the Phase III IMbrave150 Study of Atezolizumab Plus Bevacizumab versus Sorafenib in Patients with Unresectable Hepatocellular Carcinoma.

Ahmed O KasebYinghui GuanBetul Gok YavuzAlexander R AbbasShan LuElshad HasanovHan Chong TohWendy VerretYulei Wang

Published in: Journal of hepatocellular carcinoma (2022)

Baseline and kinetic change of IGF-CTP and IGF-1 scores are independent prognostic factors for patients with unresectable HCC treated with atezolizumab-bevacizumab or sorafenib. These novel scores may provide improved patient stratification in future HCC clinical trials. IMbrave150 ClincialTrials.gov number, NCT03434379.

Keyphrases

phase iii
prognostic factors
clinical trial
open label
pi k akt
binding protein
locally advanced
growth hormone
phase ii
liver metastases
metastatic colorectal cancer
double blind
case report
signaling pathway
squamous cell carcinoma
radiation therapy